Allergan will present new data from investigational Bimatoprost sustained-release (SR) at the annual meeting of the American Glaucoma Society (AGS) to be held in Washington, DC. Data from the phase 3 ARTEMIS studies will be presented during an oral session and will provide visual field (VF) outcomes and effects of Bimatoprost SR on disease progression in patients with open-angle glaucoma (OAG). A new drug application (NDA) for Bimatoprost SR is currently under review with the FDA, and if approved, has the potential to be the first and only biodegradable, intracameral implant indicated to reduce IOP in patients with open-angle glaucoma or ocular hypertension via a sustained-release drug delivery system.
“These exciting results presented at AGS reinforce our belief that Bimatoprost SR is a transformative drug that has the potential to change the treatment paradigm for people living with glaucoma,” Michael Robinson, MD, Vice President, Global Therapeutic Area Head, Ophthalmology, Allergan, said in a company news release. “There are 70 million people globally who are living with this serious and sight-threatening disease that may result in blindness and it is our commitment to ensure we are addressing their unmet needs with innovative treatments like Bimatoprost SR.”
In the same oral session, a separate presentation will feature results from the first study to quantify the effect of greater topical medication adherence on rate of glaucoma progression in a real-world patient population.
Allergan will present eight abstracts, including two oral presentations and six poster presentations (all noted in local Eastern Time):
Poster Presentations (Friday, February 28, 7:00 – 5:00 PM):
- Effect of Bimatoprost SR on IOP in Patients Previously Treated With 0, 1, or ≥2 Topical IOP-Lowering Medications: Results of Phase 3 Study at Primary Database Lock
- Authors: Craven, ER et al.
- Long-Term IOP Lowering After A Single Bimatoprost SR Administration in a Phase 1/2 Study: Relationship to Early IOP Response
- Authors: Brubaker, J et al.
- Bimatoprost Sustained-Release Implant (Bimatoprost SR) Responder Rates in Patients With Glaucoma or Ocular Hypertension: Phase 3 Study Results at Primary Database Lock
- Authors: Walters, T et al.
- Profile of IOP Response to Bimatoprost Sustained-Release Implant (Bimatoprost SR) Before Added Treatment With Topical Medication: Phase 3 Study Results
- Authors: Myers, JS et al.
- Targeted Delivery via Intracameral Administration Versus Topical Dose of 14C-Latanoprost in Animal Models.
- Authors: Shen, J et al.
Poster Presentations (Saturday, February 29, 7:00 – 4:05 PM):
- Healthcare Resource Utilization and Costs Related to Ocular Hypertension and Open-angle Glaucoma by Disease Severity
- Authors: Miller, E et al.
Oral Presentations (Saturday, February 29, 8:05 – 9:05 AM):
- Adherence to Topical Glaucoma Medications Decreases Rate of Visual Field Progression Over Time
- Authors: Fong, D et al.
- Time: 8:05 – 8:17 AM
- Visual Field Outcomes in Open-Angle Glaucoma Patients Treated With Bimatoprost SR in Phase 3 Evaluation: Results at Primary Database Lock
- Authors: Medeiros, F et al.
- Time: 8:17 – 8:29 AM